

Ilumya™ (tildrakizumab-asmn)

When requesting Ilumya™ (tildrakizumab-asmn), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Coverage Guidelines

Plaque psoriasis

For an initial authorization:

- Had a 3-month trial of or intolerance to at least one biologic therapy (e.g., adalimumab, certolizumab, etanercept, infliximab) OR
- Had a 3-month trial of or intolerance to at least one traditional systemic agent (e.g., methotrexate, cyclosporine, acitretin, psoralen plus ultraviolet A light) OR
- Is contraindicated to methotrexate therapy AND
- Is 18 years of age or older AND
- Ilumya is prescribed by or in consultation with a dermatologist

For a re-authorization:

- Has responded to Ilumya therapy

Approval duration (initial): 3 months

Approval duration (renewal): 12 months

Dosing Recommendation

The recommended dose is 100 mg administered by subcutaneous injection at weeks 0, 4, and every 12 weeks thereafter.

References

1. Ilumya™ injection [prescribing information]. Whitehouse Station, NJ: Sun Pharmaceuticals/Merck; March 2018.
2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019 Feb 13. [Epub ahead of print].
3. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC. *J Eur Acad Dermatol Venereol*. 2015;29(12):2277-2294.
4. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. *Lancet*. 2017;390(10091):276-288.